VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: biowa who wrote (1265)	6/18/1997 11:59:00 PM
From: Vector1	of 9719

<<Does Bexxar have Orphan Drug status for relapsed NHL>> PB answered this question from the 10K. Where did I get three years from? Of course IDPH uses a different conjugate Yttrium so it wouldn't be covered anyway. I know very little about Yttrium other than it is supposed to be less toxic than the radioactive iodine used in Bexxar. I would be very interested in seeing the efficacy results of YB28. In my view if Bexxar has superior efficacy there will be a market for it. I like the idea of going for a knockout punch. The concept of controlling NHL with long term MA treatment is not very appealing and this insidious disease will find a way to overcome the treatment. If I am fighting for my life I am going for the best chance of a complete remission. I am also very suspicious of partial response data. This can easily be manipulated. What is important to me is long term survival rates and complete remissions. I agree that the most recent data from IDPH is promising and should virtually guarantee their FDA approval. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next